Favourable paediatric data results in Alprolix ® product information update
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the European Commission has approved an update to the Alprolix® (eftrenonacog alfa) Summary of Product Characteristics (SmPC) to include additional information regarding use among previously untreated patients (PUPs) with haemophilia B. Alprolix is now the only extended half-life factor IX (FIX) product with safety and efficacy data in PUPs included in the SmPC. The data reinforces its favourable safety profile for use in all age groups.Philip Wood, Head of Haematology at Sobi, welcomed the news: “Today’s